Antifibrotic effect of pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 6, 2010, Pages 3061-3066

  Kim, Hyunmi ^a   Choi, Youn Hee ^a,b   Park, Soo Jung ^a   Lee, Sang Yeul ^c   Kim, Sung Joo ^d   Jou, Ilo ^a   Kook, Koung Hoon ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Kim's Eye Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; HYDROXYPROLINE; INTERLEUKIN 1BETA; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; MALE; ORBIT; ORBITAL FIBROBLAST; PRIORITY JOURNAL; WESTERN BLOTTING; ZYMOGRAPHY; CELL SURVIVAL; COMPARATIVE STUDY; CULTURE TECHNIQUE; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELL SURVIVAL; COLLAGEN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; HYDROXYPROLINE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; ORBIT; PYRIDONES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77953247863     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4257     Document Type: Article

References (37)

1. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003;24:802-835.
2. Wiersinga WM, Prummel MF. Pathogenesis of Graves' ophthalmop-athy-current understanding. J Clin Endocrinol Metab. 2001;86: 501-503.
3. El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Internal Med J. 2004;34:482-491.
4. Lee HB, Rodgers IR, Woog JJ. Evaluation and management of Graves' orbitopathy. Otolaryngol Clin North Am. 2006;39:923-942, 6.
5. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
6. Pihlajaniemi T, Myllyla R, Kivirikko KI. Prolyl 4-hydroxylase and its role in collagen synthesis. J Hepatol. 1991;13(suppl 3):S2-S7.
7. Yao HW, Zhu JP, Zhao MH, Lu Y. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration. 2006;73:236-242.
8. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274:21491-21494.
9. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
10. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
11. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573.
12. Roderfeld M, Weiskirchen R, Wagner S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J. 2006;20:444-454.
13. Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases. Clin Exp Immunol. 2005;141:388-397.
14. Oku H. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomy-cin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008; 590:400-408.
15. Kakugawa T. Pirfenidone attenuates expression of HSP47 in mu-rine bleomycin-induced pulmonary fibrosis. Eur Resp J. 2004;24: 57-65.
16. Card JW. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol Sci. 2003;75:169-180.
17. di Sario A. The antifibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Digest Liver Dis. 2004;36:744-751.
18. Tada S. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol. 2001;28:522-527.
19. Zhang S, Shiels IA, Ambler JS, Taylor SM. Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol. 1998;26(suppl 1):S74-S76.
20. Lin X, Yu M, Wu K, Yuan H, Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2009;50:3763-3770.
21. Oliver GW, Leferson JD, Stetler-Stevenson WG, Kleiner DE. Quantitative reverse zymography: analysis of picogram amounts of met-alloproteinase inhibitors using gelatinase A and B reverse zymo-grams. Anal Biochem. 1997;244:161-166.
22. Han R, Smith TJ. Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol. 2005; 174:3072-3079.
23. Vincent TL, Hermansson MA, Hansen UN, Amis AA, Saklatvala J. Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded. Arthritis Rheum. 2004; 50:526-533.
24. Karakiulakis G, Papakonstantinou E, Aletras AJ, Tamm M, Roth M. Cell type-specific effect of hypoxia and platelet-derived growth factor-BB on extracellular matrix turnover and its consequences for lung remodeling. J Biol Chem. 2007;282:908-915.
25. Ma C, Tarnuzzer RW, Chegini N. Expression of matrix metallopro-teinases and tissue inhibitor of matrix metalloproteinases in me-sothelial cells and their regulation by transforming growth factor-beta1. Wound Repair Regen. 1999;7:477-485.
26. Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocri-nol Invest. 2004;27:246-253.
27. Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthal-mopathy. J Immunol. 2005;175:1310-1319.
28. Young DA, Evans CH, Smith TJ. Leukoregulin induction of protein expression in human orbital fibroblasts: evidence for anatomical site-restricted cytokine-target cell interactions. Proc Natl Acad Sci U S A. 1998;95:8904-8909.
29. Hwang CJ, Afifiyan N, Sand D, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthal-mol Vis Sci. 2009;50:2262-2268.
30. Yoshiji H. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology. 2000;32:1248-1254.
31. Brook NR, Waller JR, Bicknell GR, Nicholson ML. The novel anti-fibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. Transplant Proc. 2005;37:130-133.
32. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol. 1998;113: 72-76.
33. Walker JE, Margolin SB. Pirfenidone for chronic progressive multiple sclerosis. Mult Scler. 2001;7:305-312.
34. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040-1047.
35. van Steensel L, Paridaens D, Schrijver B, et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2009;50:3091-3098.
36. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56:311-322.
37. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008;22:2214-2222.